Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) reported no change in its share structure for the month ended 30 June 2026, according to the company’s latest Monthly Return filed with Hong Kong Exchanges and Clearing Limited on 3 July 2026.

Registered Capital • The company’s registered share capital remained at RMB 364.59 million, represented by 364.59 million ordinary H shares with a par value of RMB 1 each. • No increase or decrease in the registered share capital was recorded during the month.

Issued Shares and Treasury Position • Issued H shares (excluding treasury shares): 364.59 million. • Treasury shares: none. • No issuance, conversion, repurchase, or cancellation of shares occurred in June, leaving the total issued share count unchanged.

Public Float Compliance • Biostar Pharmaceuticals confirmed that it met the Main Board’s minimum public-float requirement of 25% as of 30 June 2026.

Capital Structure Context • The company completed full circulation on 30 March 2026 by converting 147.87 million unlisted shares into H shares, aligning all 364.59 million registered shares with the Hong Kong market.

No Outstanding Equity Instruments • The filing shows no outstanding share options, warrants, convertible securities, or other arrangements that could dilute existing shareholders.

Overall, Biostar Pharmaceuticals’ June report reflects a stable capital structure with full adherence to Hong Kong Stock Exchange regulations and no equity transactions during the period.